Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2002 1
2003 4
2004 4
2005 2
2006 5
2007 3
2008 6
2009 8
2010 7
2011 6
2012 6
2013 9
2014 9
2015 12
2016 20
2017 22
2018 25
2019 21
2020 25
2021 33
2022 28
2023 22
2024 13

Text availability

Article attribute

Article type

Publication date

Search Results

255 results

Results by year

Filters applied: . Clear all
Page 1
Comparison of the efficacy of enfortumab vedotin between patients with metastatic urothelial carcinoma who were treated with avelumab or pembrolizumab: real-world data from a multi-institutional study in Japan.
Hirasawa Y, Adachi T, Hashimoto T, Fukuokaya W, Koike Y, Yata Y, Komura K, Uchimoto T, Tsujino T, Nishimura K, Takahara K, Saruta M, Fujita K, Hashimoto M, Uemura H, Shiroki R, Azuma T, Kimura T, Ohno Y. Hirasawa Y, et al. Among authors: fujita k. J Cancer Res Clin Oncol. 2024 Apr 9;150(4):182. doi: 10.1007/s00432-024-05717-2. J Cancer Res Clin Oncol. 2024. PMID: 38592548 Free PMC article.
Durable Response to Enfortumab Vedotin Compared to Re-challenging Chemotherapy in Metastatic Urothelial Carcinoma After Checkpoint Inhibitors.
Uchimoto T, Tsuchida S, Komura K, Fukuokaya W, Adachi T, Hirasawa Y, Hashimoto T, Yoshizawa A, Saruta M, Hashimoto M, Higashio T, Matsuda T, Nishimura K, Tsujino T, Nakamura K, Fukushima T, Nishio K, Yamamoto S, Iwatani K, Urabe F, Mori K, Yanagisawa T, Tsuduki S, Takahara K, Inamoto T, Miki J, Fujita K, Kimura T, Ohno Y, Shiroki R, Uemura H, Azuma H. Uchimoto T, et al. Among authors: fujita k. Target Oncol. 2024 Mar 28. doi: 10.1007/s11523-024-01047-y. Online ahead of print. Target Oncol. 2024. PMID: 38546942
Inflammatory myofibroblastic tumor of the prostate.
Fukiage K, Fujita K, Toyoda S, Nishimoto M, Kikuchi T, Chikugo T, Yoshimura K, Esa A, Ito A, Uemura H. Fukiage K, et al. Among authors: fujita k. IJU Case Rep. 2024 Jan 18;7(2):141-143. doi: 10.1002/iju5.12687. eCollection 2024 Mar. IJU Case Rep. 2024. PMID: 38440704 Free PMC article.
Determination of enzalutamide long-term safety and efficacy for castration-resistant prostate cancer patients after combined anti-androgen blockade followed by alternative anti-androgen therapy: a multicenter prospective DELC study.
Nagahara A, Uemura M, Sato M, Nakata W, Tsujihata M, Takao T, Matsumura S, Nishimura K, Takada S, Iwanishi T, Kobayashi Y, Ishizuya Y, Takada T, Okada K, Inoue H, Kato T, Hatano K, Kawashima A, Ujike T, Fujita K, Nonomura N. Nagahara A, et al. Among authors: fujita k. Jpn J Clin Oncol. 2024 Feb 1:hyae004. doi: 10.1093/jjco/hyae004. Online ahead of print. Jpn J Clin Oncol. 2024. PMID: 38305451
Oncologic Outcomes in Patients with Residual Upper Tract Urothelial Carcinoma Following Neoadjuvant Chemotherapy.
Fletcher SA, Pallauf M, Watts EK, Lombardo KA, Campbell JA, Rezaee ME, Rouprêt M, Boorjian SA, Potretzke AM, Roshandel MR, Ploussard G, Djaladat H, Ghoreifi A, Mari A, Campi R, Khene ZE, Raman JD, Kikuchi E, Rink M, Abdollah F, Boormans JL, Fujita K, D'Andrea D, Soria F, Breda A, Hoffman-Censits J, McConkey DJ, Shariat SF, Pradere B, Singla N. Fletcher SA, et al. Among authors: fujita k. Eur Urol Oncol. 2024 Jan 22:S2588-9311(24)00035-X. doi: 10.1016/j.euo.2024.01.010. Online ahead of print. Eur Urol Oncol. 2024. PMID: 38262800
Prognostic outcomes in patients with metastatic renal cell carcinoma receiving second-line treatment with tyrosine kinase inhibitor following first-line immune-oncology combination therapy.
Matsushita Y, Kojima T, Osawa T, Sazuka T, Hatakeyama S, Goto K, Numakura K, Yamana K, Kandori S, Fujita K, Ueda K, Tanaka H, Tomida R, Kurahashi T, Bando Y, Nishiyama N, Kimura T, Yamashita S, Kitamura H, Miyake H; Japanese Urological Oncology Group. Matsushita Y, et al. Among authors: fujita k. Int J Urol. 2024 Jan 19. doi: 10.1111/iju.15396. Online ahead of print. Int J Urol. 2024. PMID: 38240169
255 results